Brelovitug (BJT-778) is a humanized IgG1 neutralizing monoclonal antibody targeting hepatitis B surface antigen (HBsAg). Brelovitug has significant antiviral activity, and neutralizes and removes HBV and HDV as well as depleting HBsAg-containing subviral particles. Brelovitug can be used for HDV and HBV infections, chronic hepatitis delta (CHD) and chronic hepatitis B (CHB) research[1][2].
Molekulargewicht:
(143.954 kDa)
Reinheit:
99
CAS Nummer:
[3033337-14-0]
Target-Kategorie:
HBV
Anwendungsbeschreibung:
MCE Product type: Inhibitory Antibodies
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten